Dhansa Labs revenue rises 10.82%, plans Rs 30 crore expansion
Dhansa Labs reported a 10.82% increase in revenue to ₹14,153.72 lakhs and a 15.47% rise in PAT to ₹552.26 lakhs for FY26. The company announced a ₹30 crore investment to expand Atrazine manufacturing capacity, targeting ₹120-140 crores in additional revenue. Additionally, subsidiaries are developing a ₹120 crore CBG project and a biomass pellet venture, with the CBG plant set to commence operations by July 2027.

*this image is generated using AI for illustrative purposes only.
Dhansa Labs Limited reported a 10.82% year-on-year increase in revenue from operations to ₹14,153.72 lakhs for the financial year ended March 31, 2026. Profit after tax (PAT) grew by 15.47% to ₹552.26 lakhs, while EBITDA stood at ₹1,221.80 lakhs, a growth of 6.31%. The company maintained an EBITDA margin of 8.55% and a PAT margin of 3.87% during the period.
Management outlined a significant capacity expansion initiative in its core agrochemical business, including a planned addition of Atrazine manufacturing capacity. This project involves an estimated investment of approximately ₹30 crores and is expected to commence operations by August 2026. Upon stabilization, the company anticipates the project will generate additional annual revenues of ₹120 crores to ₹140 crores, with an initial target of ₹40 crores in the current year.
Diversification and Subsidiaries
The company is diversifying through its subsidiaries, Dhansa Green Energy Private Limited and Dhansa Biofuels Power Private Limited. Dhansa Green Energy is developing a 15 TPD Compressed Biogas (CBG) project in the Bundi district of Rajasthan with an estimated cost exceeding ₹120 crores. Commercial operations are expected to commence by July 2027. The project includes a lease for 350 acres to cultivate Napier grass, ensuring a sustainable feedstock ecosystem and supporting carbon credit generation.
Dhansa Biofuels Power Private Limited is focusing on biomass pellets. The total planned investment for the BioFuel segment is approximately ₹120 crores. Management stated that financial closure for the CBG project is secured, with ₹85 crores in debt finalized and the remaining funding sourced from warrants issued in August 2025.
Financial Guidance and Metrics
For the upcoming financial year, the company expects revenue growth of approximately 20%. Current capacity utilization stands at 71%. Management addressed concerns regarding working capital utilization, noting that funds raised via IPO were used to reduce creditors, increase debtors, and improve stock levels to mitigate material scarcity issues.
| Metric | FY26 Value | YoY Growth |
|---|---|---|
| Revenue from Operations | ₹14,153.72 lakhs | 10.82% |
| EBITDA | ₹1,221.80 lakhs | 6.31% |
| PAT | ₹552.26 lakhs | 15.47% |
| EBITDA Margin | 8.55% | - |
| PAT Margin | 3.87% | - |
Historical Stock Returns for Dhansa Labs
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.78% | -13.72% | -20.73% | -47.72% | -50.06% | -78.15% |
How will the company fund the remaining gap for the BioFuel segment given that financial closure is secured only for the CBG project?
What are the expected margins for the new Atrazine capacity compared to the current 8.55% EBITDA margin?
How does the company plan to bridge the gap between current 71% capacity utilization and the 20% revenue growth target for the upcoming year?


























